109 related articles for article (PubMed ID: 6170750)
1. Biotransformation and biological activity of N-(4-hydroxyphenyl)retinamide derivatives in rodents.
Swanson BN; Newton DL; Roller PP; Sporn MB
J Pharmacol Exp Ther; 1981 Dec; 219(3):632-7. PubMed ID: 6170750
[TBL] [Abstract][Full Text] [Related]
2. N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice.
Hultin TA; May CM; Moon RC
Drug Metab Dispos; 1986; 14(6):714-7. PubMed ID: 2877832
[TBL] [Abstract][Full Text] [Related]
3. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.
Hultin TA; Filla MS; McCormick DL
Drug Metab Dispos; 1990; 18(2):175-9. PubMed ID: 1971569
[TBL] [Abstract][Full Text] [Related]
4. Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-trans-retinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice.
Hultin TA; McCormick DL; May CM; Moon RC
Drug Metab Dispos; 1988; 16(6):783-8. PubMed ID: 2907453
[TBL] [Abstract][Full Text] [Related]
5. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Lewis KC; Hochadel JF
Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues.
Vratilova J; Frgala T; Maurer BJ; Patrick Reynolds C
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 808(2):125-30. PubMed ID: 15261805
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.
Swanson BN; Zaharevitz DW; Sporn MB
Drug Metab Dispos; 1980; 8(3):168-72. PubMed ID: 6104581
[TBL] [Abstract][Full Text] [Related]
8. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
9. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat.
Moon RC; Thompson HJ; Becci PJ; Grubbs CJ; Gander RJ; Newton DL; Smith JM; Phillips SL; Henderson WR; Mullen LT; Brown CC; Sporn MB
Cancer Res; 1979 Apr; 39(4):1339-46. PubMed ID: 421218
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
11. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
13. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
[TBL] [Abstract][Full Text] [Related]
14. Effects of N-(4-hydroxyphenyl)retinamide supplementation on vitamin A metabolism.
Lewis KC; Zech LA; Phang JM
Cancer Res; 1994 Aug; 54(15):4112-7. PubMed ID: 8033144
[TBL] [Abstract][Full Text] [Related]
15. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic hydrolysis of retinamides.
Shih TW; Shealy YF; Hill DL
Drug Metab Dispos; 1988; 16(3):337-40. PubMed ID: 2900722
[TBL] [Abstract][Full Text] [Related]
17. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid.
Delia D; Aiello A; Lombardi L; Pelicci PG; Grignani F; Grignani F; Formelli F; Menard S; Costa A; Veronesi U
Cancer Res; 1993 Dec; 53(24):6036-41. PubMed ID: 8261419
[TBL] [Abstract][Full Text] [Related]
18. Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis.
Chapman JS; Weiss KL; Curley RW; Highland MA; Clagett-Dame M
Arch Biochem Biophys; 2003 Nov; 419(2):234-43. PubMed ID: 14592467
[TBL] [Abstract][Full Text] [Related]
19. N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
Takahashi N; Sausville EA; Breitman TR
Clin Cancer Res; 1995 Jun; 1(6):637-42. PubMed ID: 9816026
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.
Ponzoni M; Bocca P; Chiesa V; Decensi A; Pistoia V; Raffaghello L; Rozzo C; Montaldo PG
Cancer Res; 1995 Feb; 55(4):853-61. PubMed ID: 7850799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
